getting to the heart of the matter
Novel therapeutics and diagnostics targeting the multi-factorial root causes of CVD
Can we cure and
even prevent cardiovascular disease (CVD)?
Cardiovascular Disease (CVD) is the world’s leading chronic killer impacting more than one-third of the world’s population. US direct and indirect healthcare costs due to CVD are expected to grow to an estimated $1.5 trillion by 2030. Among the top 150 developing nations worldwide, CVD is the largest health risk and cost.
Dr. J.B. Tunac, President and Chairman of Arterez, has discovered the multi-factorial upstream etiology or root causes of chronic vascular disease and that those can be identified, characterized, cured and ultimately prevented. A profound discovery indeed.
The company’s first drug, Embotricin™, targets healing at the cellular level rather than targeting symptoms. The company has also developed a biomarker panel for treatment monitoring, GlycoCardia™, that can also be used for disease identification, staging and classification.
Embotricin™ proved to prevent and reverse arterial plaques in models and proved non-toxic up to 300x the effective dose in mice. Rat in vitro and in vivo in process. First in-human studies expected to begin early 2023.
"Historical development of antibiotics targeting microorganisms led to a cure of infectious disease. An equivalent approach is to target the endothelial glycocalyx to cure CVD by an anti-embolic™ mechanism."
Dr. Joe Tunac
Offerings and IP Summary
Primary Offerings
IP Matter Description
Embotricin™
A rationally synthesized, triple compound, oral therapy with unique mechanisms of action targeting the root causes of CVD proven to prevent and reverse arterial plaques, the hallmark of CVD.
GlycoCardia™
A therapeutic aide and series of diagnostic panels that provide specific information on the associated pathology and risk factors of CVD diseases and stages based on our Glycalyx Detritus Fingerprint™ technology.
Issued 2019
Methods and Compositions for ReversingDisruption of the Glycocalyx, Inflammation andOxidative Damage.
Issued 2021
Issued Patent 2021
Biomarkers of Vascular Disease.
Pending 2019
Drug Treatment and Biomarker Panel Targeted
to Diseases Due to Multifactorial Ontology of
Glycocalyx Disruption.
PCT and other pending IP in process
